AP Sports SummaryBrief at 4:24 p.m. EST
4Th Test: Inglis Ruled Out Of Border-Gavaskar Trophy With Calf Strain
ASP Isotopes Inc. Responds to Short Seller ReportProsecutors play undercover recordings of Madigan at former speaker’s corruption trial
Enfusion's COO Neal Pawar sells $190,721 in stock
Emerging tight end Noah Gray gives Mahomes and the Chiefs another option in passing game
Pharming Group ( OTCMKTS:PHGUF – Get Free Report ) and Disc Medicine ( NASDAQ:IRON – Get Free Report ) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Analyst Recommendations This is a summary of recent ratings and price targets for Pharming Group and Disc Medicine, as reported by MarketBeat. Disc Medicine has a consensus price target of $85.80, indicating a potential upside of 32.08%. Given Disc Medicine’s stronger consensus rating and higher possible upside, analysts clearly believe Disc Medicine is more favorable than Pharming Group. Risk & Volatility Insider and Institutional Ownership 83.7% of Disc Medicine shares are held by institutional investors. 4.2% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Earnings and Valuation This table compares Pharming Group and Disc Medicine”s top-line revenue, earnings per share and valuation. Pharming Group has higher revenue and earnings than Disc Medicine. Pharming Group is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Profitability This table compares Pharming Group and Disc Medicine’s net margins, return on equity and return on assets. Summary Disc Medicine beats Pharming Group on 8 of the 14 factors compared between the two stocks. About Pharming Group ( Get Free Report ) Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. About Disc Medicine ( Get Free Report ) Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company’s preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter .
Warren Hills boys, Phillipsburg girls bowling gain confidence with Greg Rottengen Tourney titlesThe Dallas Cowboys ended five weeks of frustration with a 34-26 win at Washington in a Sunday decision overflowing with both hilarious and historic moments. And one guy who obviously feels he's earned an at-least temporary last laugh? Micah Parsons, who not once but twice last week in the buildup for this game proclaiming that his Cowboys are a "damn good football team.'' Javascript is required for you to be able to read premium content. Thanks for the feedback.
Counterpoint: Five signs our country isn’t lostWASHINGTON (AP) — President-elect Donald Trump’s allies on Capitol Hill rallied around Pete Hegseth , Trump’s Pentagon pick, on Thursday even as new details surfaced about allegations that he had sexually assaulted a woman in 2017. The GOP embrace of Hegseth came as another controversial Trump nominee, Matt Gaetz, withdrew from consideration for attorney general. Gaetz said it was clear he had become a “distraction" amid pressure on the House to release an ethics report about allegations of his own sexual misconduct. An attorney for two women has said that his clients told House Ethics Committee investigators that Gaetz paid them for sex on multiple occasions beginning in 2017, when Gaetz was a Florida congressman. Fresh questions over the two nominees' pasts, and their treatment of women, arose with Republicans under pressure from Trump and his allies to quickly confirm his Cabinet. At the same time, his transition has so far balked at the vetting and background checks that have traditionally been required. While few Republican senators have publicly criticized any of Trump's nominees, it became clear after Gaetz's withdrawal that many had been harboring private concerns about him. Oklahoma Sen. Markwayne Mullin, who served with Gaetz in the House, said it was a “positive move.” Mississippi Sen. Roger Wicker said it was a “positive development.” Maine Sen. Susan Collins said Gaetz “put country first and I am pleased with his decision.” After meeting with Hegseth, though, Republicans rallied around him. “I think he’s going to be in pretty good shape,” said Wicker, who is expected to chair the Senate Armed Services Committee in the next Congress. Republican senators' careful words, and their early reluctance to publicly question Trump's picks, illustrated not only their fear of retribution from the incoming president but also some of their hopes that the confirmation process can proceed normally, with proper vetting and background checks that could potentially disqualify problematic nominees earlier. Gaetz withdrew after meeting with senators on Wednesday. Sen. Thom Tillis said Gaetz was “in a pressure cooker” when he decided to withdraw, but suggested that it would have little bearing on Trump’s other nominees. “Transactions — one at a time,” he said. As the Hegseth nomination proceeds, Republicans also appear to be betting that they won't face much backlash for publicly setting aside the allegations of sexual misconduct — especially after Trump won election after being found liable for sexual abuse last year. Hegseth held a round of private meetings alongside incoming Vice President JD Vance on Thursday in an attempt to shore up support and told reporters afterward: “The matter was fully investigated and I was completely cleared, and that’s where I’m gonna leave it.” A 22-page police report report made public late Wednesday offered the first detailed account of the allegations against him. A woman told police that she was sexually assaulted in 2017 by Hegseth after he took her phone, blocked the door to a California hotel room and refused to let her leave. The report cited police interviews with the alleged victim, a nurse who treated her, a hotel staffer, another woman at the event and Hegseth. Hegseth’s lawyer, Timothy Palatore, said the incident was “fully investigated and police found the allegations to be false.” Hegseth paid the woman in 2023 as part of a confidential settlement to head off the threat of what he described as a baseless lawsuit, Palatore has said. Wicker played down the allegations against Hegseth, a former Fox News host, saying that “since no charges were brought from the authorities, we only have press reports.” Sen. Bill Hagerty, R-Tenn., said after his meeting with Hegseth that he "shared with him the fact that I was saddened by the attacks that are coming his way.” Hagerty dismissed the allegations as “a he-said, she-said thing” and called it a “shame” that they were being raised at all. The senator said attention should instead be focused on the Defense Department that Hegseth would head. It's one of the most complex parts of the federal government with more than 3 million employees, including military service members and civilians. Sexual assault has been a persistent problem in the military, though Pentagon officials have been cautiously optimistic they are seeing a decline in reported sexual assaults among active-duty service members and the military academies. Wyoming Sen. John Barrasso, who will be the No. 2 Republican in the Senate next year, said after his meeting with Hegseth that the nominee is a strong candidate who “pledged that the Pentagon will focus on strength and hard power – not the current administration’s woke political agenda.” Senate Republicans are under pressure to hold hearings once they take office in January and confirm nominees as soon as Trump is inaugurated, despite questions about whether Trump’s choices will be properly screened or if some, like Hegseth, have enough experience for the job. Senate Armed Services Chairman Jack Reed, who will be the top Democrat on the panel next year, said the reports on Hegseth “emphasized the need for a thorough investigation by the FBI on the background of all the nominees.” It takes a simple majority to approve Cabinet nominations, meaning that if Democrats all opposed a nominee, four Republican senators would also have to defect for any Trump choice to be defeated. Trump has made clear he’s willing to put maximum pressure on Senate Republicans to give him the nominees he wants – even suggesting at one point that they allow him to just appoint his nominees with no Senate votes. But senators insist, for now, that they are not giving up their constitutional power to have a say. “The president has the right to make the nominations that he sees fit, but the Senate also has a responsibility for advice and consent,” said Republican Sen. Mike Rounds of South Dakota. In the case of Gaetz, he said, “I think there was advice offered rather than consent.” Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Stay up-to-date on the latest in local and national government and political topics with our newsletter.